Ç Â. Ê. åîïìïëïãåßôáé (2)...

Girl Çìïõí ç ðñþôç ðïõ åîïìïëïãÞèçêå ôéò åìðåéñßåò ôçò óå áõôÞ åäþ ôç óåëßäá.

Ôï ìáêñïóêåëÝóôáôï, áãùíéþäåò êåßìåíï ôï åß÷á ãñÜøåé ãýñù óôï 1997. Ôï åß÷á êñáôÞóåé (ôá äñÜìáôá äåí ôá ðåôïýóá ôüôå) êáé ôï äçìïóéåýóá åäþ, üôáí åßäá üôé ìðïñþ.
¹èåëá íá ìïéñáóôþ ôá ìáýñá óõíáéóèÞìáôá êáé ôéò óêïôåéíÝò óêÝøåéò åêåßíïõ ôïõ êáéñïý.
Äåí ìïõ áñêïýóå íá æïýí ìÝóá ìïõ, Þèåëá íôå êáé êáëÜ íá ôïõò äþóù ðåñéóóüôåñï ÷þñï íá æÞóïõí, íá áðëùèïýí ôá ìÝãéóôá!

ÓÞìåñá, 10 ÷ñüíéá ìåôÜ, èÝëù íá îáíáãñÜøù ìåñéêÜ ëüãéá.
¢ëëáîá, êáé èÝëù íá ìïéñáóôþ ìáæß óáò ôá "íÝá"!

Ôçí éäÝá íá ôï êÜíù ôçí ðÞñá áðü êÜðïéá êåßìåíá/åîïìïëïãÞóåéò ðïõ äéÜâáóá óÞìåñá, ìå ôá ïðïßá ôáõôéæüìïõí ðñéí 8-10 ÷ñüíéá êáé ðïõ óÞìåñá äåí ìå åêöñÜæïõí óå ôßðïôá.

ÌÝóá óôá 12 ÷ñüíéá ðïõ åßìáé ïñïèåôéêÞ, Ýêáíá (äüîá ôù Èåþ) êÜðïéåò åíáëëáêôéêÝò åñùôÞóåéò óôïí åáõôü ìïõ:
á) Âñå ìðáò êáé äåí åßìáé êõñßùò ìéá ïñïèåôéêÞ?
Äçë. ó÷åäüí ìüíï Ýíáò éüò ìå ðüäéá? Áò ñßîù áìÝóùò ìéá ìáôéÜ êáé óôéò õðüëïéðåò ðïéüôçôÝò ìïõ, ôá ÷áñßóìáôÜ ìïõ, ôéò ïìïñöéÝò ìïõ.
Áò ôïõò äþóù ôïí ÷þñï êáé ôç óçìáóßá ðïõ ôïõò áîßæåé... êáé ìÝóá óå üëï ôï ôïðßï áð' üóá ìå óõíèÝôïõí êáé ìå áöïñïýí, óå ìéá ãùíßôóá, áò âÜëù êáé ôçí "éäéüôçôá" ôçò ïñïèåôéêÞò ãéá öüíôï.
â) Âñå ìðáò êáé áõôÞ ç áóèÝíåéá Ý÷åé íá "ìïõ ðåß" ðñÜãìáôá ãéá ìÝíá?
ÌÞðùò öÝñíåé ìçíýìáôá ãéá ôçí ðÜñôç ìïõ? ÌÞðùò ìïõ åðéóçìáßíåé ðùò åß÷á ðÜñåé Ýíáí äñüìï ìáêñéÜ áðü ôçí øõ÷ïýëá ìïõ, êé åðåéäÞ ôüôå äåí Üêïõãá êáíÝíáí êáé êõñßùò ôïí åáõôü ìïõ, âñÞêå ç óïöÞ öýóç Ýíáí äõíáìéêü ôñüðï íá ìïõ ôï ðåß?
Ìðáò êáé áõôüò ï åöéÜëôçò áí ôïí ãõñßóù áð' ôçí Üëëç, äéáâÜóù ðùò Ý÷åé êáé ìéá Üëëç ðéèáíÞ ôáõôüôçôá? ÌÞðùò åÜí ôïõ ôï åðéôñÝøù èá ìðïñïýóå íá ëåéôïõñãÞóåé óáí ðéèáíÞ åõêáéñßá?

H ðñáãìáôéêüôçôá åßíáé èÝìá åñìçíåßáò. ¼ðùò ôçí ïíïìÜóåéò, áíôáðïêñßíåôáé. Åìåßò ïñßæïõìå ôçí ôáõôüôçôá ôùí óõìâÜíôùí êáé óôç óõíÝ÷åéá ðñïêáëïýìå êáé ôéò áíÜëïãåò åêâÜóåéò ôïõò, óêÝöôçêá..

Êáé åôÝèç åðåßãïí ôï åñþôçìá: ÊáôáóôñïöÞ Þ åõêáéñßá?

ÐÞñá óôá óïâáñÜ ôéò åñùôÞóåéò ìïõ êáé âÜëèçêá íá äþóù áðáíôÞóåéò.
Ç æùÞ ìïõ Üëëáîå. Ç øõ÷Þ ìïõ Üëëáîå. Ôï Óýìðáí Üëëáîå.
Êáé áõôÞ ç áëëáãÞ ìå ïäÞãçóå óôçí ôåëåõôáßá åñþôçóç:

Âñå ìðáò êáé ç åßäçóç "áíßáôç áóèÝíåéá" äåí åßíáé íôå êáé êáëÜ áëÞèåéá? Áíßáôç áð'Ýîù, áðü ôçí ðëåõñÜ ôïõ ãéáôñïý ï ïðïßïò ôï äçëþíåé. ÌÞðùò êáé åöüóïí ï Üíèñùðïò åßíáé öïñÝáò áõôïúáóçò, èá ìðïñïýóå ìéá ðéèáíÞ ßáóç íá Ýñèåé áðü ìÝóá?

ÕðïèÝôù ðùò èá öÜù êÜðïéåò äéáäéêôõáêÝò ìïýíôæåò ìå ôï êåßìåíü ìïõ. Åßíáé äåêôÝò. Èá óáò óõíéóôïýóá üìùò íá êñáôÞóåôå êáé ìéá ãéá ôïí åáõôü óáò! ¼ðùò Ýêáíá êé åãþ êÜðïôå.

×áéñåôþ ôïõò óõìðáèÝóôáôïõò ößëïõò ðïõ óôçñßæïõí ôï óÜéô áõôü!

Â.Ê




... 'Aëëåò éóôïñßåò ...

+/-
ÌÜèå ôï status óïõ

Âñåò ôï ãéáôñü óïõ

ÐÜñå èåñáðåßá

¸ëåãîå ôï ééêü óïõ öïñôßï

Lancet

Ðñüóöáôåò äçìïóéåýóåéò óôï ðåñéïäéêü The Lancet HIV

Another step towards closing the paediatric treatment gap

Expanding access to antiretroviral therapy (ART) and reducing new HIV acquisitions among women has led to a marked decline in vertical HIV transmission over the past decade. Nevertheless, in 2023 alone, an estimated 120 000 children aged 0–14 years acquired HIV globally, with the vast majority living in Africa.1 Without treatment, over half of infants and young children with perinatally acquired HIV die before their second birthday.2 Early diagnosis and timely linkage to care are therefore essential to reducing morbidity and mortality.

Deworming of filariasis and reduction of HIV incidence

In sub-Saharan Africa, lymphatic filariasis and HIV infection are two major public health problems that often coexist.1 For several decades, scientists have been exploring the negative impact of helminth infections, including the filarial nematode Wucheria bancrofti, on HIV acquisition and pathogenesis.1–3 Immunological studies have tried to validate the anecdotal, but biologically plausible, theory that modulatory effects of helminths such as W bancrofti can affect HIV infection.3–5 However, some of these studies were inconclusive, and many were characterised by two common flaws, cross-sectional design1 or small sample size,3 weakening the strength of the evidence.

Modelling study shows staggering impact of HIV funding cuts

The global AIDS response has seen substantial reductions in HIV incidence and number of deaths.1 The greatest improvements have been recorded in sub-Saharan Africa, the region with the worst HIV burden. Many of the advances are attributed to international funding of national programmes within sub-Saharan Africa. International contributions were estimated to be 41% of total HIV expenditure in low-income and middle-income countries (LMICs) in 2023.1 Over the last 5–10 years there have been reported declines in HIV funding from both domestic contributions and non-US international funders.

About us

Óôï hivaids.gr, öéëïîåíïýìå áöéëïêåñäþò ôï "Ðñüãñáììá Óõíåñãáóßáò" ÌïíÜäùí Ëïéìþîåùí ãéá ôçí áíÜðôõîç äéáäéêôõáêÞò ôñÜðåæáò êëéíéêþí ðáñáìÝôñùí. Ôï Ðñüãñáììá äçìéïõñãÞèçêå áðü Ýíáí ãéáôñü åéäéêü óôçí HIV ëïßìùîç ìå ôç óõììåôï÷Þ ôùí ÌïíÜäùí: Ðåñéóóüôåñá

% Áíáðçñßá êáé HIV

ÍÝïò êáíïíéóìüò

Åíéáßïò Ðßíáêáò Ðñïóäéïñéóìïý Ðïóïóôïý Áíáðçñßáò

Çìåñïëüãéï

@ Äéáýãåéá

ÄéáýãåéáÄé@ýãåéá

äéáöÜíåéá óôï êñÜôïò

ÄéáäéêôõáêÝò áíáñôÞóåéò äéïéêçôéêþí áðïöÜóåùí ãéá ôï HIV/AIDS

Twitter

¸ñåõíá

Óáò Ý÷åé óðÜóåé ðïôÝ ôï ðñïöõëáêôéêü êáôÜ ôç äéÜñêåéá ìéáò åñùôéêÞò åðáöÞò;
Íáé
¼÷é
Äåí ÷ñçóéìïðïéþ

Åðéêïéíùíßá

Newsletter

Áíáêïéíþóåéò

×ñÞóéìåò ðëçñïöïñßåò

ÔçëåöùíéêÞ ãñáììÞ ãéá ôï HIV/AIDS

210-7222222

ÄåõôÝñá - ÐáñáóêåõÞ
09:00 - 21:00